ArticleThe ISME journal2026
Deoxycholate induces proline provision from Escherichia coli to enhance Clostridioides difficile virulence.
Article in The ISME journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Clostridioides difficile infection (CDI) is a refractory enteritis. A key indicator of successful treatment and microbial restoration is the elevation of intestinal deoxycholate (DCA) levels. Nevertheless, a small proportion of patients experience disease recurrence despite this apparent metabolic recovery, the underlying mechanisms of which remain poorly understood. We investigated the ecological dynamics of Clostridioides difficile (CD) and Escherichia coli (EC) under DCA exposure, revealing that DCA exacerbates the severity of co-infection. Specifically, DCA promotes the formation of a robust and dense symbiotic biofilm that confers a substantial survival advantage to CD. Through a combination of in vitro co-culture and validation in a murine infection model, we demonstrated that EC produces substantial quantities of L-proline in response to DCA. This amino acid is converted to D-proline by the proline racemase and subsequently catabolized by the D-proline reductase in CD, thereby enhancing its environmental fitness and pathogenicity within the gut. The indispensable nature of this tripartite interaction was further corroborated using additional EC or CD strains, including isogenic mutants deficient in D-proline reductase, in subsequent murine infection models. These experiments collectively confirm that EC, proline, and the D-proline reductase are all essential components mediating the DCA-induced exacerbation of CDI. In summary, our study elucidates a mechanism by which a DCA environment promotes the exacerbation of CDI through a metabolic cross-feeding interaction between CD and EC. Specifically, EC-derived L-proline serves as a critical nutrient that enhances the fitness and pathogenicity of CD. This finding provides a plausible explanation for the paradoxical phenomenon of CDI recurrence in patients exhibiting elevated intestinal DCA levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.